SLC9A1 and heart failure: Because of the extensive experimental evidence that NHE1 participates in cardiacpathologies including ischemia and reperfusion injury as well as myocardialremodeling and heart failure (discussed in Sections 6 and 7) there has beensubstantial interest in inhibition of NHE1 and in the development of clinicallyuseful compounds for treatment of the diseased myocardium.